EW

Edwards Lifesciences Corporation designs, manufactures and markets medical devices that treat structural heart disease, chiefly transcatheter aortic valve replacement (TAVR) systems, transcatheter mitral and tricuspid repair/replacement technologies, and surgical heart‑valve products. The company operates within the medical‑technology sector, focusing on cardiovascular devices and, until its recent divestiture, critical‑care monitoring solutions. It is recognized as a global leader in structural‑heart innovations, with its SAPIEN TAVR platform and expanding portfolio giving it a dominant market position across aortic, mitral and tricuspid therapies. Its business model relies on direct sales to hospitals and partnerships with clinicians worldwide, leveraging a strong pipeline of minimally invasive heart‑valve technologies.